Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
Transcript (slightly modified)
Why do we need value calculators and the value discussion in oncology today?
Value in oncology care today is a very important topic because the effectiveness of therapies but also because of the cost—both to society and to the individual patient—of the individual therapies. And so it's a circumstance where it's important to know what the consumer, what the healthcare system is getting in return for the dollar cost that is being spent on cancer care. It's very complicated and providing transparent information either by text, tables, or computer-based calculators is very important.
What are the cornerstones of NCCN's Evidence Blocks?
The NCCN Evidence Blocks are based upon 5 different dimensions of data or decision making. The first is the dimension of efficacy: how effective is the therapy? The second is safety: how safe is it to receive the therapy, what kind of difficulties or toxicities would the patient experience with the therapy? The third is that of data quality and quantity that supports the recommendation. The fourth is the consistency of the information that supports the recommendation. And the fifth is that of affordability and how affordable is the therapy to the medical system or society.
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More